Precision Antithrombotic Therapy

The study enrolls two distinct patient populations:

Thrombotic Disease Patients (4,000 subjects):

Age ≥ 8 years

Diagnosed with one of the following conditions requiring long-term anticoagulation:

Non-valvular atrial fibrillation (CHA₂DS₂-VA score ≥ 1) Venous thromboembolism (deep vein thrombosis or pulmonary embolism) Other indications for NOACs in thrombotic disease prevention/treatment Currently receiving NOAC therapy (rivaroxaban, apixaban, dabigatran, or edoxaban) Willing and able to comply with study protocol and follow-up schedule Signed informed consent

Ischemic Stroke Patients (1,000 subjects):

Age ≥ 18 years Assessed as high bleeding risk within 72 hours after symptom onset First-time treatment with indobufen after hospital admission Willing and able to comply with study protocol and follow-up schedule Signed informed consent

Inclusion criteria:

• Age ≥ 8 years old;
• Diagnosed with one of the following diseases and in need of long - term anticoagulant therapy: non - valvular atrial fibrillation (CHA₂DS₂ - VA score ≥ 1); venous thromboembolism (deep vein thrombosis or pulmonary embolism); having other indications for using NOACs to prevent and treat thrombotic diseases;
• Currently receiving NOAC treatment (rivaroxaban, apixaban, dabigatran etexilate, edoxaban);
• Willing and able to comply with the requirements of the research protocol and the follow - up plan;
• Signed the informed consent form.
• Age ≥ 18 years old;
• Assessed as patients at high risk of bleeding within 72 hours after the onset of symptoms;
• Receiving indobufen treatment for the first time after admission;
• Willing and able to comply with the requirements of the research protocol and the follow - up plan;
• Signed the informed consent form.

Exclusion criteria:

• Having contraindications to the use of NOACs or being allergic to NOACs;
• Having been enrolled in other clinical trials.
• Being allergic to or having contraindications to indobufen;
• Needing to change antithrombotic drugs or combine with other antiplatelet/anticoagulant therapies (such as clopidogrel, ticagrelor, warfarin, heparin, etc.) during the study;
• Cardiogenic stroke or stroke induced by angioplasty/vascular surgery;
• Having a history of aneurysm (intracranial or peripheral);
• Severe abnormal liver and kidney functions;
• Pregnant, lactating women or women of childbearing age who are unwilling to take effective contraceptive measures;
• Life expectancy < 1 year;
• Mental or emotional disorders preventing cooperation with follow - up;
• Participating in other clinical trials within 30 days before enrollment;
• Unable to complete blood concentration detection (such as difficulty in establishing venous access).